Tag Archives: Obamacare

The Sovaldi Case: Is American Biotech History About to Repeat Itself?

Recent Congressional investigations over the pricing scheme of Gilead’s much-heralded hepatitis C drug Sovaldi – and a decline in stocks across the biotech sector – rings a familiar bell, writes Tom Norton. Twenty years ago in May, US Senator Joe Lieberman carefully questioned biotech CEO Harry Penner of then Neurogen Corporation about why his company’s […]
Posted in Biotech, healthcare, leadership, Market Access, pricing, R&D, Sales, Strategy | Also tagged , , , , , , , , | 2 Comments

"Close Call" for American Rx Marketers on Medicare Part D

As the U.S. heads towards a public market place in which Medicare, Medicaid, CHIPs, VA, and now Obamacare will shortly comprise almost 70% of the American healthcare market, American Rx marketers recently endured a “close call” with the U.S. Department of Health and Human Services over the arbitrary deletion of dozens of key drugs from […]
Posted in Marketing, Op-Ed, Regulatory | Also tagged , , , | Leave a comment

2014: End of the Road for the American Rx Salesperson?

2014: End of the Road for the American Rx Salesperson? “The only thing you’ve got in this world is what you can sell.” Willy Loman Death of a Salesman During my years with two major U.S. pharmaceutical companies, some of the most interesting individuals I got to know were field salespersons.  Certainly one of my […]
Posted in Guest Blog, Op-Ed, Sales | Also tagged , , , , , | 17 Comments

Obamacare: Questions for Pharma in 2014

Tom Norton outlines the Obamacare-related questions that are likely to be of concern to pharma companies in the U.S. this year. I t’s expected that about 35 new FDA approved prescription drugs will arrive on the market in 2014. What are the chances that these new medications will be utilized by Obamacare health programs?  Given […]
Posted in Guest Blog, healthcare, Op-Ed, Regulatory | Also tagged , , , , | 2 Comments

Budget Options Will Reshape Healthcare

While the struggle continues in 2014 to provide effective and affordable coverage, administration and Congressional leaders will weigh a host of spending options important to coverage and delivery. Federal outlays for healthcare and health-related federal tax benefits exceed $1 trillion a year, according to the Congressional Budget Office (CBO). These and related spending on discretionary […]
Posted in Guest Blog, healthcare, Regulatory | Also tagged , , | Leave a comment
  • Categories

  • Meta